
CLAIMS

1. An oral pharmaceutical formulation comprising

a compound of formula (**I**):



(**I**)

or its co-crystal; wherein X^- is a pharmaceutically acceptable anion selected from halide or a carboxylate ion or X^- is absent;

a) a permeability enhancing agent selected from sodium caprylate, sodium caprate sodium laurate and sodium oleate or

b) a base selected from organic base, inorganic base, phosphate buffer and salt of carboxylic acid comprising less than 5 carbon atoms or

c) a mixture thereof;

and optionally other pharmaceutically acceptable excipients.

2. The formulation according to claim 1, wherein halide is chloride.

3. The formulation according to claim 1, wherein carboxylate ion is caprate.

4. The formulation according to claim 1, wherein permeability enhancing agent is sodium caprate.

5. The formulation according to claims 1 or 4, wherein a permeability enhancing agent is present in an amount from about 0.02% to about 75% w/w of total formulation; preferably in an amount from about 2.5% to about 60% w/w of total formulation; most preferably in an amount from about 5% to about 30% w/w of total formulation.

6. The formulation according to claim 1, wherein inorganic base is selected from magnesium carbonate and sodium bicarbonate.

7. The formulation according to claim 1, wherein organic base is selected from meglumine and arginine.

8. The formulation according to claim 1, wherein base is present in an amount from about 0.002% to about 60% w/w of total formulation, preferably in an amount from about 0.2% to about 25%w/w of total formulation, more preferably in an amount from about 0.5% to about 15.0% w/w of total formulation, most preferably in an amount from about 0.5% to about 5% w/w of total formulation.

9. The formulation according to claim 1, wherein compound of formula (I) and a permeability enhancing agent is in the form of conjugate.

10. The formulation according to claim 1, wherein compound of formula (I) or its co-crystal is present in amount from about 0.1% to about 80% w/w of total formulation, preferably in an amount from about 0.25% to about 70% w/w of total formulation, most preferably in an amount of about 5% to about 50% w/w of total formulation.

11. Use of formulation according to claim 1 in the manufacture of a medicament for treating disease condition selected from diabetes and aging related macrovascular and microvascular complications including heart failure, nephrological disorder, neuropathy, atherosclerosis and retinal disorder; dermatological disorder; endothelial or other organ dysfunction and growth impairment.

12. The formulation according to claim 1, wherein formulation comprises from 150 mg to 1500 mg of compound of formula (I) or its co-crystal.

13. The formulation according to claim 12, wherein formulation comprises from 250 mg to 750 mg of compound of formula (I) or its co-crystal.